Pomegra
Vaderis closes $152M Series B to fund Phase 3 of engasertib, set to become the first-ever approved therapy for HHT, a rare vascular disorder affecting 1 in 3,800.
- Vaderis closed a $152.5M oversubscribed Series B on Aug. 11, 2026, co-led by Goldman Sachs Alternatives Life Sciences and TCGX.
- Engasertib targets HHT, a rare genetic disorder affecting 1 in 3,800 people, and has no existing approved therapy worldwide.
- Proof-of-concept data in the NEJM showed the 40mg dose cut nosebleed duration by 41%, clearing the bar for a pivotal trial.
Lead
Vaderis Therapeutics, a Basel-based clinical-stage biotech, closed a $152.5 million oversubscribed Series B financing on August 11, co-led by Goldman Sachs Alternatives Life Sciences and TCGX. Joining the round were Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing backers Medicxi and Droia. The proceeds fund the HEROIC study, a global Phase 3 trial of engasertib (VAD044) in patients with hereditary hemorrhagic telangiectasia (HHT) - a rare inherited vascular disorder that has gone over 130 years without a single approved therapy. Valuation was not disclosed.
What Is HHT - and Why Has Nothing Been Approved?
HHT is a genetic disorder that causes abnormal blood vessel connections - arteriovenous malformations - throughout the body. The most visible symptom is recurrent, often severe nosebleeds, but patients also develop AVMs in the lungs, liver, and brain, which can cause life-threatening hemorrhage or stroke. An estimated two million people worldwide live with the condition, yet the drug development community largely left it alone. The patient population is small, the biology was complex, and until recently no clean therapeutic target existed.
Engasertib changes that calculus. The drug is an oral, once-daily selective allosteric inhibitor of AKT1 and AKT2 - proteins in a signaling pathway that governs abnormal blood vessel growth. Blocking AKT reduces aberrant vessel formation at the root of HHT, rather than managing individual bleeds symptomatically.
What Did the Clinical Data Actually Show?
The Series B follows a critical scientific milestone: publication of Vaderis' proof-of-concept and long-term extension data for engasertib in The New England Journal of Medicine. The 12-week randomized, placebo-controlled study showed dose-dependent improvements in HHT symptoms. At the 40mg dose - selected for Phase 3 - patients saw a 41% reduction in nosebleed duration and a 28% reduction in frequency, against 24% and 18% for placebo. Long-term extension data indicated the effects were durable.
Publishing a controlled trial in the NEJM before initiating Phase 3 is an unusual sequence, and it reflects both the strength of the signal and the absence of any approved benchmark. With no standard of care to compare against, Vaderis built its Phase 3 design around the same endpoints where engasertib already showed clear separation.
The HEROIC Trial and the Regulatory Path
The HEROIC study is a global Phase 3 trial enrolling patients with moderate-to-severe HHT. Vaderis structured the financing to carry the program through regulatory submissions and potential U.S. approval - a timeline that implies several years of burn at late-clinical spending rates. The $152.5 million raise is large by Series B standards even in biopharma; it reflects both the capital intensity of a global pivotal trial and institutional appetite for rare-disease assets with NEJM-grade proof of concept behind them.
EQT Life Sciences alone deployed $17.5 million. The investor mix - combining crossover-stage funds with specialist rare-disease allocators - suggests Vaderis is already mapping a path toward an IPO or partnership with a larger orphan-drug commercial platform before any approval decision.
What This Round Implies About the Last One
Vaderis raised a small Series A backed by Medicxi and Droia to run the proof-of-concept work. A $152.5 million Series B to follow represents a meaningful step-up in both scale and investor profile, and carries an implicit signal that early backers were satisfied enough to bring in new lead investors rather than bridge the company to a narrow milestone. Whether that confidence holds through a global Phase 3 execution is a different question.
Outlook
Vaderis enters Phase 3 with cleaner data than most rare-disease programs carry into a pivotal trial. The NEJM publication eliminates one layer of scientific uncertainty; what remains is execution risk at global trial scale and the regulatory question of which endpoints will satisfy both the FDA and EMA for a first-ever HHT approval. If HEROIC succeeds, engasertib becomes the only approved therapy for a condition that has been documented in medicine for more than a century and treated, in practice, with watchful waiting. For the investor syndicate behind this round, the oversubscription is a statement of conviction. The Phase 3 data will determine whether it was justified.
